Cardiol Therapeutics Inc Class A CRDL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
-
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
-
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
-
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
-
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Trading Information
- Previous Close Price
- $1.20
- Day Range
- $1.14–1.18
- 52-Week Range
- $0.88–2.34
- Bid/Ask
- $1.13 / $1.15
- Shares Outstanding
- 121.51M
- Market Cap
- $139.75M
- Volume/Avg
- 443,119 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 18
- Website
- https://www.cardiolrx.com
Valuation
|
Metric
|
CRDL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.32 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRDL
|
|---|---|
Quick Ratio | 5.01 |
Current Ratio | 5.55 |
Interest Coverage | — |
Quick Ratio
CRDL
Profitability
|
Metric
|
CRDL
|
|---|---|
Return on Assets (Normalized) | −101.47% |
Return on Equity (Normalized) | −145.41% |
Return on Invested Capital (Normalized) | −139.04% |
Return on Assets
CRDL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|qlYjGKb | LOCK|hTMh | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|^WpYsQ^ | LOCK|#bCl | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|k?lKSX | LOCK|<$^ | $41B | |||
| Zoetis Inc Class A
ZTS
| LOCK|$DZpQbxf | LOCK|@&! | $31B | |||
| Viatris Inc
VTRS
| LOCK|yM%#%l | LOCK|XkR | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|RL | LOCK|rK | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|$x<V%zs | LOCK|?d | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|D%#wkD | LOCK|H! | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|W$%?nz | LOCK|SkJ%% | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|!<$@n@f | LOCK|Ph | $2B |
United States